Literature DB >> 22081322

Simultaneous transcatheter aortic and mitral valve-in-valve implantation in a patient with degenerated bioprostheses and high surgical risk.

M Seiffert1, S Baldus, L Conradi, D Koschyk, J Schirmer, T Meinertz, H Reichenspurner, H Treede.   

Abstract

Transcatheter valve-in-valve implantation is evolving as a promising alternative to reoperative valve replacement in selected high-risk patients, considering the increasing need for redo surgery due to bioprosthetic degeneration in the future. Reoperative double valve replacements are particularly associated with an elevated surgical risk. The transapical access provides the opportunity to approach the aortic and mitral valves during one intervention. We report the case of a successful transcatheter valve-in-valve implantation in the aortic and mitral position within a single procedure. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2011        PMID: 22081322     DOI: 10.1055/s-0031-1280368

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  3 in total

1.  Simultaneous transcatheter valve-in-valve replacement of severely degenerated bioprosthetic aortic and mitral prostheses.

Authors:  Hendrik Wienemann; Victor Mauri; Elmar Kuhn; Stephan Baldus; Matti Adam
Journal:  Clin Res Cardiol       Date:  2022-08-04       Impact factor: 6.138

Review 2.  Transcatheter valve-in-valve therapies: patient selection, prosthesis assessment and selection, results, and future directions.

Authors:  Manuel Wilbring; Konstantin Alexiou; Sems-Malte Tugtekin; Bjoern Sill; Gregor Simonis; Klaus Matschke; Utz Kappert
Journal:  Curr Cardiol Rep       Date:  2013-03       Impact factor: 2.931

Review 3.  Transcatheter mitral valve implantation for degenerated mitral bioprostheses or failed surgical annuloplasty rings: A systematic review and meta-analysis.

Authors:  Junjie Hu; Yan Chen; Sijin Cheng; San Zhang; Kaiqin Wu; Wenli Wang; Yongxin Zhou
Journal:  J Card Surg       Date:  2018-07-10       Impact factor: 1.620

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.